We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Protective actions of a luminally acting 5‐HT<sub>4</sub> receptor agonist in mouse models of colitis.
- Authors
Hurd, Molly; Haag, Melody M.; Kwasnik, Matthew J.; Wykosky, Jill; Lavoie, Brigitte; Mawe, Gary M.
- Abstract
Background: 5‐hydroxytryptamine 4 receptors (5‐HT4Rs) are expressed in the colonic epithelium, and previous studies have demonstrated that luminal administration of agonists enhances motility, suppresses nociception, and is protective in models of inflammation. We investigated whether stimulation with a luminally acting 5‐HT4R agonist is comparable to previously tested absorbable compounds. Methods: The dextran sodium sulfate (DSS), trinitrobenzene sulfonic acid (TNBS), and interleukin 10 knockout (IL‐10KO) models of colitis were used to test the protective effects of the luminally acting 5‐HT4R agonist, 5HT4‐LA1, in the absence and presence of a 5‐HT4R antagonist. The compounds were delivered by enema to mice either before (prevention) or after (recovery) the onset of active colitis. Outcome measure included disease activity index (DAI) and histological evaluation of colon tissue, and effects on wound healing and fecal water content were also assessed. Key Results: Daily enema of 5HT4‐LA1 attenuated the development of, and accelerated recovery from, active colitis. Enema administration of 5HT4‐LA1 did not attenuate the development of colitis in 5‐HT4R knockout mice. Stimulation of 5‐HT4Rs with 5HT4‐LA1 increased Caco‐2 cell migration (accelerated wound healing). Daily administration of 5HT4‐LA1 did not increase fecal water content in active colitis. Conclusions and Inferences: Luminally restricted 5‐HT4R agonists are comparable to absorbable compounds in attenuating and accelerating recovery from active colitis. Luminally acting 5‐HT4R agonists may be useful as an adjuvant to current inflammatory bowel disease (IBD) treatments to enhance epithelial healing.
- Subjects
COLITIS; INFLAMMATORY bowel diseases; LABORATORY mice; SEROTONIN receptors; SODIUM sulfate
- Publication
Neurogastroenterology & Motility, 2023, Vol 35, Issue 11, p1
- ISSN
1350-1925
- Publication type
Article
- DOI
10.1111/nmo.14673